Asset
ERSODETUG
REZOLUTE INC. COMMON STOCK (NV)
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06881992 | phase3 | recruiting | 2025-04-16 | 2027-09-01 | Rezolute | A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism |
| NCT06208215 | phase3 | active_not_recruiting | 2024-01-11 | 2025-11-14 | Rezolute | RZ358 Treatment for Congenital Hyperinsulinism |
FDA applications (0)
This company has no applications containing this asset.